CStone Pharmaceuticals (HKG:2616)

Market Cap	5.82B
Revenue (ttm)	433.34M
Net Income (ttm)	-97.06M
Shares Out	1.36B
EPS (ttm)	-0.08
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,359,500
Average Volume	18,595,566
Open	4.290
Previous Close	4.290
Day's Range	4.240 - 4.380
52-Week Range	1.070 - 4.930
Beta	0.14
RSI	57.60
Earnings Date	Aug 21, 2025

About CStone Pharmaceuticals

CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in China and internationally. The company offers Sugemalimab, a monoclonal antibody against programmed death (PD) ligand 1; GAVRETO, a RET inhibitor for the treatment of patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor to treat adults with unresectable or metastatic gastrointestinal stromal tumors harborin...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 135
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2616

Financial Performance

In 2024, CStone Pharmaceuticals's revenue was 407.21 million, a decrease of -12.21% compared to the previous year's 463.84 million. Losses were -91.21 million, -75.16% less than in 2023.

Financial numbers in CNY